What are the best treatments for Sanfilippo Syndrome?

Currently, there is no curative treatment for Sanfilippo Syndrome (MPS III), so clinical management focuses on supportive, multidisciplinary care to address specific symptoms and improve quality of life. Emerging research, including gene therapy and enzyme replacement therapy trials, offers hope for future disease-modifying interventions, though these remain experimental at this time.

What is the current standard of care for Sanfilippo Syndrome?

Because Sanfilippo Syndrome is a progressive metabolic condition caused by the body's inability to break down heparan sulfate, treatment is primarily palliative. Physicians focus on managing the systemic impact of the disease, which affects the nervous, respiratory, and musculoskeletal systems. Currently, clinical guidelines prioritize symptom management, such as using anticonvulsants for seizures, specialized educational support for cognitive delays, and physical therapy to address contractures and mobility issues. In the DiseaseMaps community, 114 members have shared their experiences, highlighting the importance of a coordinated, personalized care plan that adapts as the disease progresses.

What medications and therapies are used to manage symptoms?

While no drug can yet reverse the damage caused by Sanfilippo Syndrome, several interventions are utilized to improve daily comfort:

• Substrate Reduction Therapy: Agents like genistein isoflavones are sometimes explored to reduce the buildup of storage material.


• Secondary Management: Medications such as miglustat (Zavesca), typically used for Gaucher disease, may be considered to address secondary storage issues.


• Symptom Control: Melatonin or other sleep aids are often prescribed to manage the severe insomnia common in Sanfilippo Syndrome patients.


• Therapeutic Support: Physical therapy, occupational therapy, and speech therapy are essential to maintain motor function and communication skills for as long as possible.

What are the latest developments in Sanfilippo Syndrome research?

The landscape for Sanfilippo Syndrome is evolving rapidly through clinical trials. Researchers are currently investigating gene therapy and enzyme replacement therapy (ERT) specifically for types A and B, aiming to address the underlying genetic deficiency. Additionally, trehalose sugar has been studied for its potential autophagy-inducing effects—a process that helps cells clear accumulated waste. Studies conducted by organizations like the Team Sanfilippo Foundation in partnership with Seelos Therapeutics have explored intravenous delivery of these compounds to determine their safety and efficacy in slowing the progression of Sanfilippo Syndrome.

Which specialists should be on the care team?

Effective management of Sanfilippo Syndrome requires a multidisciplinary approach due to the wide range of affected body systems. A typical care team should include:

• Metabolic Geneticist: To oversee the overall management of the metabolic disorder.


• Neurologist: To monitor seizures and cognitive decline.


• Physiatrist and Physical Therapist: To manage contractures and mobility.


• Pulmonologist: To monitor and treat recurring respiratory illnesses.


• Psychologist/Behavioral Specialist: To assist with hyperactivity and behavioral challenges.

Next steps

• Consult with a board-certified metabolic specialist to discuss the latest clinical trial eligibility for Sanfilippo Syndrome.


• Connect with the 114 members on DiseaseMaps.org to share experiences and coping strategies.


• Reach out to the National MPS Society or the Team Sanfilippo Foundation for resources on patient advocacy and research updates.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your personal medical team for diagnosis and treatment decisions specific to your situation.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Sanfilippo syndrome.


• Orphanet: Mucopolysaccharidosis type III.


• OMIM (Online Mendelian Inheritance in Man): Mucopolysaccharidosis IIIA, IIIB, IIIC, and IIID.


• National MPS Society: Resources for Sanfilippo Syndrome families.